Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2010

View Archived Issues

Preclinical data presented on Radius Health's SARM RAD-140

New class of toluidine sulfonamides set to enter clinical testing for the treatment of MM

New ligands of dopamine and/or serotonin 5-HT1A receptors reported

French scientists claim new cannabinoid CB2 receptor agonists

New inhibitors of HCV RNA-directed RNA polymerase claimed

Actelion discloses new agonists of formylpeptide FPR2/ALX receptors

Vertex modifies phase II trial of telaprevir plus VX-222 against hepatitis C

FBS-0701 is safe in phase Ib study in subjects with iron overload, phase II trial under way

Pan-5-HT1 receptor antagonist GSK-163090 progresses to clinical development

Potent analgesic activity seen with KD-7332 in vitro and in vivo

Novo Nordisk and Emisphere to develop oral insulin for diabetes

Applications for abiraterone acetate submitted to FDA and EMA

Oncothyreon begins phase I/II trial of PX-866/cetuximab combination

CHMP recommends approval of Teysuno for treatment of advanced gastric cancer

Ambit Biosciences begins phase I trials for AC-430 and AC-480

Chugai and Dainippon Sumitomo to conduct phase I/II trial of cancer vaccine WT-4869

CHMP recommends a variation to marketing terms for Simponi

CHMP recommends marketing authorization for Janssen-Cilag's Xeplion

Merck & Co. identifies new inhibitors of PDE10A

AstraZeneca discontinues motavizumab development for RSV

DSMB recommends continuation of phase II AX-200 efficacy trial

MAP Pharmaceuticals completes final trial for Levadex NDA submission

Isis begins phase I ISIS-APOCIIIRx trial to treat hypertriglyceridemia

Amarillo Biosciences to study oral interferon and Tamiflu for influenza

Amylin submits initial sections of rolling BLA for metreleptin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...